Portal:AOP/Mission

From WikiPathways

Revision as of 20:34, 8 October 2020

The purpose of this portal is to create a collection of AOPs on the molecular level for the AOPs that are, or will be created for the EU-ToxRisk program, in which Open PHACTS Foundation (OPF) is responsible for AOP creation. The subjects of the first AOPs are linked to the use cases of the EU-ToxRisk program, and there will be a team of experts involved in the creation of each AOP.

The proposed list of the first set of AOPs to be created, some are more defined than others:

• Chemical-induced bile duct obstruction leads to liver failure
• Chemical-induced bile duct obstruction leads to nephrotoxicity
• Inhibition of N-linked glycosylation leads to liver injury
• Mitochondrial complex inhibition leading to liver injury
• Inhibition of mitochondrial complex I of nigra-striatal neurons leads to parkinsonian motor deficits
• Peripheral neuropathy caused by microtubule interacting drugs
• Oxidative reactivity leads to chemical-induced fanconi syndrome
• Binding to complex I of the electron transport chain leading to chemical-induced Fanconi syndrome
• Intracellular accumulation of chemicals via the megalin/cubulin system leading to tubulonephritis
• Oxidant-induced pulmonary emphysema
• α-diketone-induced bronchiolitis obliterans
• HDAC inhibition leads to neural tube defects
• Cyp17 inhibition leads to undescended testes
• Oxidative stress-induced liver injury
• IKK complex inhibition leads to liver failure
• HDAC inhibition leads to impaired craniofacial development

Basic strategies and principles for general AOPs are described in this paper:

Villeneuve et al. (2014). Adverse Outcome Pathway (AOP) Development I: Strategies and Principles. Toxicological Sciences PubMed

The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact Marvin Martens.